An estimated 1 in 55 women in the United States will develop ovarian cancer in her lifetime. While there is no standard screening test for the disease, many risk factors and symptoms have recently been identified to help women monitor their bodies and catch the disease in its earliest stages, when it is easiest to treat. Dr. Julian Schink, head of Gynecologic Oncology at Northwestern Memorial Hospital, discusses these various factors along with several preventative measures and treatment options.
Not all women are equally likely to develop ovarian cancer. Women with a family history of ovarian or breast cancer and/or who test positive for the gene mutation BRCA 1 or 2 have a much greater risk. Dr. Schink stresses the importance of a patient listening to her body and being assertive with her doctor in addressing any changes she may notice. The doctor names a number of these symptoms and says the key to diagnosing the cancer is the frequency or amount of the symptoms.
Learn about the role ultrasounds and the blood test CA 125 can play in detecting the disease. During the program, Dr. Schink explains the cornerstone to treatment and elaborates about improvements in success rates in relation to aggressive surgery followed by chemotherapy. Also, touched on is the most promising biologic agent to date, Avastin, and how it may work in combination with other therapies. Lastly, learn why participating in a clinical trial can be extremely beneficial, particularly for ovarian cancer patients.
|
Julian Schink, M.D.
Gynecologic Oncologist, Northwestern Memorial Hospital
Julian C. Schink, M.D., is chief of the division of Gynecologic Oncology at Northwestern Memorial and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, the only National Cancer Institute-designated cancer center in Illinois. He has recently been named medical director of the Robert H. Lurie Comprehensive Cancer Center. Dr. Schink also is professor of Obstetrics and Gynecology at...
more >
|
|
|

